Indefinite Delivery Contract SPE2DU25D9386

The contract awarded to DMS Pharmaceutical Group Inc. is an Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) under the SPE2DB program, valued at $499,999,999 and valid through November 2026. The IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. The contract covers various product categories such as injections, tablets, creams, auto-injectors, and specialty medications, positioning DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain and providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites.

The contract was awarded as a result of a solicitation for the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) issued by the DLA Troop Support Medical Supply Chain. The purpose of this acquisition is to establish Prime Vendor Contracts for the PPV-G program, which provides worldwide pharmaceutical support to the Defense Health Agency (DHA), Department of Defense (DoD) customers, the United States Coast Guard, Designated Providers, Other Government Agencies, and the US Naval Fleet, including the Hospital Ships USNS Mercy and USNS Comfort. The solicitation is expected to be issued in March 2024 and remain open for 45 days, with the Government intending to make multiple Primary Supplier awards on a regional basis and one award for the Back-Up supplier.